Natera Inc’s recent filing unveils that its PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon unloaded Company’s shares for reported $0.68 million on Jan 02 ’26. In the deal valued at $228.95 per share,2,951 shares were sold. As a result of this transaction, Moshkevich Solomon now holds 123,499 shares worth roughly $30.72 million.
Then, Chapman Steven Leonard sold 3,848 shares, generating $881,482 in total proceeds. Upon selling the shares at $229.08, the CEO AND PRESIDENT now owns 136,568 shares.
Before that, SOLOMON MOSHKEVICH bought 2,951 shares. Natera Inc shares valued at $675,621 were divested by the Officer at a price of $228.95 per share.
A number of analysts have revised their coverage, including BNP Paribas Exane’s analysts, who increased its forecast for the stock in late October from “an Underperform” to “a Neutral”. RBC Capital Mkts started covering the stock on March 13, 2025. It rated NTRA as “an Outperform”.
Price Performance Review of NTRA
On Tuesday, Natera Inc [NASDAQ:NTRA] saw its stock jump 4.77% to $248.74. Over the last five days, the stock has gained 7.54%. Natera Inc shares have risen nearly 54.88% since the year began. Nevertheless, the stocks have risen 8.58% over the past one year. While a 52-week high of $246.90 was reached on 01/06/26, a 52-week low of $125.38 was recorded on 01/02/26.
Levels Of Support And Resistance For NTRA Stock
The 24-hour chart illustrates a support level at 241.06, which if violated will result in even more drops to 233.37. On the upside, there is a resistance level at 252.79. A further resistance level may holdings at 256.83.
How much short interest is there in Natera Inc?
A steep rise in short interest was recorded in Natera Inc stocks on 2025-12-15, dropping by -0.36 million shares to a total of 3.4 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 3.76 million shares. There was a decline of -10.64%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 23, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $200 price target.
